June 6 (Reuters) - Biomea Fusion said on Thursday the U.S. Food and Drug Administration had placed a clinical hold on its ongoing early-to-mid stage study of its experimental drug for type 1 and 2 diabetes, sending its shares down 55.7% in extended trade. (Reporting by Puyaan Singh in Bengaluru)